Envestnet Asset Management Inc. trimmed its position in Bio-Rad Laboratories, Inc. (NYSE:BIO – Free Report) by 1.7% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 103,224 shares of the medical research company’s stock after selling 1,803 shares during the quarter. Envestnet Asset Management Inc. owned about 0.37% of Bio-Rad Laboratories worth $25,141,000 at the end of the most recent reporting period.
Other large investors have also recently made changes to their positions in the company. World Investment Advisors purchased a new position in shares of Bio-Rad Laboratories during the first quarter valued at approximately $286,000. IFM Investors Pty Ltd raised its stake in Bio-Rad Laboratories by 7.0% in the first quarter. IFM Investors Pty Ltd now owns 3,445 shares of the medical research company’s stock worth $839,000 after buying an additional 226 shares in the last quarter. Principal Financial Group Inc. raised its stake in Bio-Rad Laboratories by 0.5% in the first quarter. Principal Financial Group Inc. now owns 44,343 shares of the medical research company’s stock worth $10,800,000 after buying an additional 236 shares in the last quarter. Teacher Retirement System of Texas acquired a new position in shares of Bio-Rad Laboratories during the first quarter worth $693,000. Finally, DAVENPORT & Co LLC increased its position in shares of Bio-Rad Laboratories by 14.1% during the first quarter. DAVENPORT & Co LLC now owns 96,605 shares of the medical research company’s stock worth $23,529,000 after purchasing an additional 11,928 shares in the last quarter. 65.24% of the stock is owned by institutional investors.
Bio-Rad Laboratories Price Performance
NYSE:BIO opened at $247.52 on Wednesday. The firm’s fifty day moving average is $237.68 and its two-hundred day moving average is $268.02. The firm has a market cap of $6.74 billion, a price-to-earnings ratio of -3.25 and a beta of 0.95. Bio-Rad Laboratories, Inc. has a one year low of $211.43 and a one year high of $387.99. The company has a debt-to-equity ratio of 0.18, a quick ratio of 4.43 and a current ratio of 5.99.
Wall Street Analysts Forecast Growth
A number of equities analysts have recently issued reports on BIO shares. Wall Street Zen downgraded Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a research report on Sunday. Wells Fargo & Company dropped their price objective on shares of Bio-Rad Laboratories from $260.00 to $245.00 and set an “equal weight” rating on the stock in a report on Monday, June 9th. UBS Group dropped their price objective on shares of Bio-Rad Laboratories from $355.00 to $310.00 and set a “buy” rating on the stock in a report on Friday, May 2nd. Citigroup dropped their price objective on shares of Bio-Rad Laboratories from $400.00 to $350.00 and set a “buy” rating on the stock in a report on Friday, May 2nd. Finally, Royal Bank Of Canada dropped their price objective on shares of Bio-Rad Laboratories from $409.00 to $392.00 and set an “outperform” rating on the stock in a report on Friday, May 2nd. Two investment analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. According to data from MarketBeat, Bio-Rad Laboratories presently has a consensus rating of “Moderate Buy” and an average target price of $324.25.
View Our Latest Stock Analysis on Bio-Rad Laboratories
Bio-Rad Laboratories Company Profile
Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.
See Also
- Five stocks we like better than Bio-Rad Laboratories
- What is MarketRank� How to Use it
- JPMorgan Q2 Results Affirm Dividend, Buybacks, & Growth
- What Makes a Stock a Good Dividend Stock?
- Goldman Spotlights These 3 Stocks in Its Bullish S&P 500 Outlook
- How to Short a Stock in 5 Easy StepsĀ
- Fastenal Surges After Earnings Beat, Tariff Risks Loom
Want to see what other hedge funds are holding BIO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bio-Rad Laboratories, Inc. (NYSE:BIO – Free Report).
Receive News & Ratings for Bio-Rad Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.